

West Africa House
Hanger Lane
Ealing
London W5 3QR
UK

T: +44 (0)20 8799 8200
F: +44 (0)20 8799 8201
E: enquiries@antisoma.com
W: www.antisoma.com

RECEIVED

2006 JUN 29 P 1:45

OFFICE OF INTERNATIONAL
CORPORATE FINANCE

ANTISOMA

Exemption number: 82-34926

Office of International Corporate Finance
Division of Corporate Finance
Mail Stop 3628
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
U.S.A.

Friday, 23 June 2006

Ladies and Gentlemen:



06014763

SUPPL

Antisoma plc

Pursuant to Rule 12g3-2(b) under the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"), we hereby furnish you with certain documentation that we have made public or filed with the UK Listing Authority, the London Stock Exchange or the Registrar of Companies for England and Wales at Companies House or distributed to our shareholders and which is listed in Annex 1 to this letter.

These documents supplement the information previously provided with respect to Antisoma plc's request for exemption under Rule 12g3-2(b), which was established on November 21, 2005.

This information is being furnished with the understanding that such information and documents will not be deemed "filed" with the SEC or otherwise subject to the liabilities of Section 18 of the Exchange Act, and that neither this letter nor the furnishing of such documents and information shall constitute an admission for any purpose that Antisoma plc is subject to the Exchange Act.

Please do not hesitate to contact the undersigned at +44 20 8799 8200 in the United Kingdom if you have any questions.

Thank you for your attention.

Yours faithfully
For and on behalf Antisoma plc

Name: Simone Tinney
Title: Communication Assistant

RECEIVED

JUN 30 2006 E

THOMSON
FINANCIAL

llw 6/29

**Antisoma to present at Needham & Company
Fifth Annual Biotechnology Conference on 15 June 2006**

13 June 2006, London, UK – Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces that its Chief Executive Officer, Glyn Edwards, will be presenting at the Needham & Company Fifth Annual Biotechnology and Medical Technology Conference in New York, USA.

Mr Edwards's presentation is scheduled for 13.00 EST on Thursday, June 15, followed by a 30 minute breakout session. A webcast of the presentation will be available to all on Antisoma's website at www.antisoma.com.

It is recommended that viewers log on 15 minutes early in order to register and download any necessary software.

Enquiries:

Margherita Lupi
Communications Manager
Antisoma plc

+44 (0)20 8799 8200

Background on Antisoma

Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.com for further information.

Antisoma to present at Piper Jaffray Health Care Conference

20 June 2006, London, UK – Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces that Glyn Edwards, its Chief Executive Officer, will present at Piper Jaffray's first London Health Care Conference on Friday 23 June at 12.00 BST.

Enquiries:

Margherita Lupi
Communications Manager

+44 (0)20 8799 8200

Background on Antisoma

Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.com for further information.